Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Update

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 20,300 shares, a decrease of 49.9% from the December 31st total of 40,500 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is currently 0.7 days.

Inhibitor Therapeutics Price Performance

Shares of OTCMKTS:INTI traded down $0.01 during trading on Wednesday, reaching $0.06. 10,000 shares of the stock were exchanged, compared to its average volume of 19,289. The stock has a fifty day moving average of $0.07 and a two-hundred day moving average of $0.07. Inhibitor Therapeutics has a 1-year low of $0.03 and a 1-year high of $0.14. The firm has a market cap of $9.58 million, a price-to-earnings ratio of -5.56 and a beta of -0.56.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.